The anti-CTL4, anti-PD1, or anti-PD-L1 antibodies, called immune checkpoint inhibitors (ICI), bind either receptor or ligands to augment the previously acquired T-cell responses against tumor cells. The gene discussed is CD274; the disease is neoplasm.